174 related articles for article (PubMed ID: 37941480)
1. Targeting hyperactive platelet-derived growth factor receptor-β signaling in T-cell acute lymphoblastic leukemia and lymphoma.
De Coninck S; De Smedt R; Lintermans B; Reunes L; Kosasih HJ; Reekmans A; Brown LM; Van Roy N; Palhais B; Roels J; Van der Linden M; Van Dorpe J; Ntziachristos P; Van Delft FW; Mansour MR; Pieters T; Lammens T; De Moerloose B; De Bock CE; Goossens S; Van Vlierberghe P
Haematologica; 2024 May; 109(5):1373-1384. PubMed ID: 37941480
[TBL] [Abstract][Full Text] [Related]
2. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
3. Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-cell acute lymphoblastic leukemia.
Ávila Ávila A; Nuantang K; Oliveira ML; Druillennec S; Zaniboni B; Lengliné E; Asnafi V; Ghysdael J; Tran Quang C
Blood; 2024 May; 143(21):2166-2177. PubMed ID: 38437728
[TBL] [Abstract][Full Text] [Related]
4. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
5. Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma.
Provez L; Putteman T; Landfors M; Roels J; Reunes L; T'Sas S; Van Loocke W; Lintermans B; De Coninck S; Thenoz M; Sleeckx W; Maćkowska-Maślak N; Taghon T; Mansour MR; Farah N; Norga K; Vandenberghe P; Kotecha RS; Goossens S; Degerman S; De Smedt R; Van Vlierberghe P
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765607
[TBL] [Abstract][Full Text] [Related]
6. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene.
Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A
Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835
[TBL] [Abstract][Full Text] [Related]
7. Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia.
Bontoux C; Simonin M; Garnier N; Lhermitte L; Touzart A; Andrieu G; Bruneau J; Lengliné E; Plesa A; Boissel N; Baruchel A; Bertrand Y; Molina TJ; Macintyre E; Asnafi V
Mod Pathol; 2022 Sep; 35(9):1227-1235. PubMed ID: 35562412
[TBL] [Abstract][Full Text] [Related]
8. Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
[TBL] [Abstract][Full Text] [Related]
9. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
[TBL] [Abstract][Full Text] [Related]
10. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
11. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
[TBL] [Abstract][Full Text] [Related]
12. A novel fusion gene involving PDGFRB and GCC2 in a chronic eosinophilic leukemia patient harboring t(2;5)(q37;q31).
Iriyama N; Takahashi H; Naruse H; Miura K; Uchino Y; Nakagawa M; Iizuka K; Hamada T; Hatta Y; Nakayama T; Takei M
Mol Genet Genomic Med; 2019 Apr; 7(4):e00591. PubMed ID: 30697976
[TBL] [Abstract][Full Text] [Related]
13. Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 Protocols.
Michaux K; Bergeron C; Gandemer V; Mechinaud F; Uyttebroeck A; Bertrand Y;
Pediatr Blood Cancer; 2016 Jul; 63(7):1214-21. PubMed ID: 27037853
[TBL] [Abstract][Full Text] [Related]
14. Concurrent acute myeloid leukemia and T lymphoblastic lymphoma in a patient with rearranged PDGFRB genes.
Chang H; Chuang WY; Sun CF; Barnard MR
Diagn Pathol; 2012 Feb; 7():19. PubMed ID: 22356850
[TBL] [Abstract][Full Text] [Related]
15. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
Candoni A; Lazzarotto D; Petruzzellis G
Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
[TBL] [Abstract][Full Text] [Related]
16. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
17. Early T-Cell Precursor Leukemia: A High-Risk Subtype of Acute Lymphoblastic Leukemia, Single Center Experience in Jordan.
Halahleh K; Muradi I; Khalil MZ; Halahleh L; Sughayer M; Kamal N; Sultan I; Alrabi K
Clin Lymphoma Myeloma Leuk; 2023 Nov; 23(11):e411-e419. PubMed ID: 37730482
[TBL] [Abstract][Full Text] [Related]
18. BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma.
Tian XP; Cai J; Ma SY; Fang Y; Huang HQ; Lin TY; Rao HL; Li M; Xia ZJ; Kang TB; Xie D; Cai QQ
Cancer Commun (Lond); 2020 Jun; 40(6):245-259. PubMed ID: 32459053
[TBL] [Abstract][Full Text] [Related]
19. Promoter swapping of truncated PDGFRB drives Ph-like acute lymphoblastic leukemia.
Miyazaki B; Ueno T; Sugiyama M; Kojima S; Arakawa A; Tao K; Tanimura K; Shiraishi K; Yagishita S; Kohsaka S; Kato M; Kiyokawa N; Goto Y; Yatabe Y; Hamada A; Mano H; Ogawa C; Tanaka Y
NPJ Precis Oncol; 2023 Dec; 7(1):132. PubMed ID: 38071343
[TBL] [Abstract][Full Text] [Related]
20. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.
Cain JA; Xiang Z; O'Neal J; Kreisel F; Colson A; Luo H; Hennighausen L; Tomasson MH
Blood; 2007 May; 109(9):3906-14. PubMed ID: 17218386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
